Knight Therapeutics | GUD - Debt


Knight Therapeutics reported CAD77.91M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Acasti Pharma USD 0 0 Sep/2024
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Aurora Cannabis CAD 23.86M 76.48M Mar/2026
Avita Medical AUD 46.05M 1.46M Dec/2025
Canopy Growth CAD 278.71M 19.38M Mar/2026
Cronos Group USD 1.51M 233K Dec/2025
Dianthus Therapeutics USD 1.36M 79K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
IQVIA Holdings USD 15.83B 109M Mar/2026
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
Moderna USD 1.31B 571M Dec/2025
Omeros USD 442.16M 199K Sep/2023
Organigram Holdings CAD 8.2M 554K Mar/2026
Organon & Co USD 8.57B 75M Mar/2026
Revvity USD 3.4B 29.2M Dec/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
Tilray USD 640.95M 35.17M Jun/2022
Viatris USD 14.34B 69.3M Mar/2026
Xeris Pharmaceuticals USD 258.55M 899K Mar/2026